BRD4-BD1-IN-2

CAS No. 2761321-26-8

BRD4-BD1-IN-2( —— )

Catalog No. M35765 CAS No. 2761321-26-8

BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 μM, exhibiting 20-fold greater inhibitory activity against BRD4-BD1 compared to BRD4-BD2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 603 Get Quote
5MG 922 Get Quote
10MG 1121 Get Quote
25MG 1454 Get Quote
50MG 1822 Get Quote
100MG 2250 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BRD4-BD1-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 μM, exhibiting 20-fold greater inhibitory activity against BRD4-BD1 compared to BRD4-BD2.
  • Description
    BRD4-BD1-IN-2 is a selective BRD4-BD1 inhibitor, with an IC50 of 2.51 μM (20-times greater than that of BD2). BRD4-BD1-IN-2 can be used in studies of cancer and cardiovascular diseases.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2761321-26-8
  • Formula Weight
    583.07
  • Molecular Formula
    C20H15Br3N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(N1C2=C(N=C1Br)N(C)C(=O)N(CC3=CC=C(Br)C=C3)C2=O)C4=CC=C(Br)C=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chang Y, et al. Design, synthesis, biological evaluation, and molecular docking of 1, 7-dibenzyl-substituted theophylline derivatives as novel BRD4-BD1-selective inhibitors. Medicinal Chemistry Research, 2021, 30(8): 1453-1468.
molnova catalog
related products
  • C-82

    C-82 is a specific CBP/β-catenin antagonist. It inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300.

  • GSK778 hydrochloride

    GSK778 hydrochloride hydrochloride is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively.

  • BY27

    BY27, a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1/BD2 of BRD2, BRD3, BRD4, and BRDT, and suppresses tumor growth.